한글목차

세계의 액체 색전제 시장은 2024년에 2억 5,548만 달러로 평가되며, 2030년에는 CAGR 6.38%로 3억 6,613만 달러에 달할 것으로 예측됩니다.

액체 색전제는 중재적 방사선 치료시 비정상적인 혈관이나 혈류를 막는 데 사용되는 특수 의료용 물질입니다. 이 약제들은 일반적으로 신경혈관 및 말초혈관 질환의 치료에 사용되며, 영상 유도 하에 카테터를 통해 투여됩니다. 시장 확대의 주요 요인 중 하나는 특히 고령화 사회에서 혈관 관련 질환이 전 세계에서 증가하고 있다는 점입니다.

또한 최소침습 수술에 대한 선호도가 높아지면서 시장 성장을 지원하고 있습니다. 이러한 수술은 일반적으로 합병증이 적고, 입원 기간이 짧으며, 전반적인 의료 비용을 절감할 수 있기 때문입니다. 이러한 긍정적인 추세에도 불구하고 시장은 몇 가지 문제에 직면해 있습니다. 특히 중저소득 국가에서는 색전술 및 색전제 자체와 관련된 높은 비용이 큰 장벽이 될 수 있습니다.

주요 시장 성장 촉진요인

헬스케어 산업의 성장

주요 시장 이슈

전문 기술 및 교육의 필요성

주요 시장 동향

종양 질환의 유병률 증가

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 COVID-19가 세계의 액체 색전제 시장에 미치는 영향

제5장 세계의 액체 색전제 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 제품 유형별(에틸렌 비닐 알코올 공중합체(EVOH), 시아노아크릴레이트, 기타)
  • 용도별(동정맥 기형(AVM), 혈관 증식성 종양, 말초혈관 출혈, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 액체 색전제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 액체 색전제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 액체 색전제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 액체 색전제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 액체 색전제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 촉진요인
• 과제

제12장 시장 동향과 발전

• 합병과 인수
• 제품 출시
• 최근 동향

제13장 혼란 : 분쟁, 팬데믹, 무역장벽

제14장 세계의 액체 색전제 시장 : SWOT 분석

제15장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제16장 경쟁 구도

• Johnson & Johnson Services, Inc.
• Medtronic Plc
• B. Braun SE
• Terumo Corporation
• Boston Scientific Corporation
• Balt
• Blacks wan Vascular, Inc.
• INVAMED
• Meril
• Gem srl

제17장 전략적 제안

제18장 조사회사 소개·면책사항

영문목차

Global Liquid Embolic Agent Market was valued at USD 255.48 Million in 2024 and is expected to reach USD 366.13 Million by 2030 with a CAGR of 6.38%. Liquid embolic agents are specialized medical substances used to occlude (block) abnormal blood vessels or blood flow during interventional radiology procedures. These agents are typically used in the treatment of neurovascular and peripheral vascular diseases and are administered via catheters in image-guided settings. One of the primary factors contributing to market expansion is the global rise in vascular-related diseases, particularly in aging populations.

Additionally, the growing preference for minimally invasive surgical techniques is supporting market growth, as these procedures generally result in fewer complications, shorter hospital stays, and reduced overall healthcare costs. Despite these favorable trends, the market faces certain challenges. The high cost associated with embolization procedures and the embolic agents themselves can be a significant barrier, especially in low- and middle-income countries.

Key Market Drivers

Growth in Healthcare Industry

The ongoing expansion of the global healthcare industry serves as a significant catalyst for the growth of the liquid embolic agent market. The global healthcare industry generates annual sales exceeding USD 4 trillion. The most significant and profitable segments are pharmaceuticals and biotechnology, with revenues approaching USD 850 billion, followed by medical technology and diagnostics, which generate over USD 400 billion. As healthcare infrastructure improves and investment in advanced medical technologies increases worldwide, the demand for minimally invasive procedures particularly in the fields of interventional radiology and neurovascular treatment continues to rise.

Liquid embolic agents, which are critical in procedures such as the treatment of arteriovenous malformations (AVMs), aneurysms, and tumors, are benefiting directly from these trends. For instance, Onyx has proven to be a safe and effective option for the embolization of brain arteriovenous malformations (AVMs). It enables complete obliteration in smaller AVMs, while larger AVMs can be sufficiently reduced in size to facilitate subsequent surgical or radiosurgical intervention. The rising prevalence of chronic conditions, especially neurological and oncological disorders, has further heightened the need for targeted, safe, and effective embolization solutions.

Key Market Challenges

Need for Specialized Skills and Training

A significant challenge facing the global liquid embolic agent market is the critical need for specialized skills and comprehensive training among healthcare professionals. The administration of liquid embolic agents requires advanced technical expertise, as these procedures involve precise catheter navigation and controlled delivery of embolic materials within complex vascular structures. Ensuring procedural success and minimizing risks such as non-target embolization or vessel damage depend heavily on the proficiency of interventional radiologists, neurosurgeons, and related specialists.

However, there is a notable shortage of adequately trained personnel with the necessary experience and knowledge to perform these highly intricate procedures, particularly in emerging and underdeveloped regions. The lack of standardized training programs and limited access to hands-on learning opportunities further exacerbate this issue. This skills gap poses a barrier to the widespread adoption of liquid embolic agents, restricting their availability to select medical centers with specialized expertise.

Key Market Trends

Rising Prevalence of Oncology Conditions

The increasing incidence of oncology-related conditions worldwide is emerging as a prominent trend driving the growth of the global liquid embolic agent market. In 2022, there were approximately 20 million new cancer diagnoses and 9.7 million cancer-related deaths globally. The estimated number of individuals surviving at least five years post-diagnosis reached 53.5 million. Statistically, one in five people will develop cancer during their lifetime, with mortality rates of approximately one in nine for men and one in twelve for women.

With cancer cases on the rise due to factors such as aging populations, lifestyle changes, and environmental influences, there is a growing demand for innovative and minimally invasive treatment options. Liquid embolic agents play a critical role in oncological interventions, particularly in the targeted management of tumors through embolization techniques. These agents are used to selectively block blood flow to tumors, thereby inhibiting their growth and enhancing the effectiveness of adjunct therapies such as chemotherapy and radiation.

Key Market Players

• Johnson & Johnson Services, Inc.
• Medtronic Plc
• B. Braun SE
• Terumo Corporation
• Boston Scientific Corporation
• Balt
• Blacks wan Vascular, Inc.
• INVAMED
• Meril
• Gem srl

Report Scope

In this report, the Global Liquid Embolic Agent Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Liquid Embolic Agent Market, By Product Type:

• Ethylene Vinyl Alcohol Copolymer (EVOH)
• Cyanoacrylates
• Others

Liquid Embolic Agent Market, By Application:

• Arteriovenous Malformations (AVM)
• Hypervascularity Tumors
• Peripheral Vasculature Haemorrhage
• Others

Liquid Embolic Agent Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Liquid Embolic Agent Market.

Available Customizations:

Global Liquid Embolic Agent Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Liquid Embolic Agent Market

5. Global Liquid Embolic Agent Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Ethylene Vinyl Alcohol Copolymer (EVOH), Cyanoacrylates, Others)
  • 5.2.2. By Application (Arteriovenous Malformations (AVM), Hypervascularity Tumors, Peripheral Vasculature Haemorrhage, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Liquid Embolic Agent Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Liquid Embolic Agent Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Mexico Liquid Embolic Agent Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Canada Liquid Embolic Agent Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Application

7. Europe Liquid Embolic Agent Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Liquid Embolic Agent Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Liquid Embolic Agent Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Liquid Embolic Agent Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Liquid Embolic Agent Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Liquid Embolic Agent Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Liquid Embolic Agent Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Liquid Embolic Agent Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Liquid Embolic Agent Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Application
  • 8.3.3. South Korea Liquid Embolic Agent Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Application
  • 8.3.4. Japan Liquid Embolic Agent Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Liquid Embolic Agent Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Application

9. South America Liquid Embolic Agent Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Liquid Embolic Agent Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Liquid Embolic Agent Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Liquid Embolic Agent Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Liquid Embolic Agent Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Liquid Embolic Agent Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Liquid Embolic Agent Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Liquid Embolic Agent Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Global Liquid Embolic Agent Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Johnson & Johnson Services, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Medtronic Plc
• 16.3. B. Braun SE
• 16.4. Terumo Corporation
• 16.5. Boston Scientific Corporation
• 16.6. Balt
• 16.7. Blacks wan Vascular, Inc.
• 16.8. INVAMED
• 16.9. Meril
• 16.10. Gem srl

17. Strategic Recommendations

18. About Us & Disclaimer